Symrise stock rises on organic growth beat By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2025
0mins
Should l Buy ?
Source: Investing.com
Sales Performance: Symrise's first-quarter sales reached €1,317 million, slightly below estimates, but the company reported stronger-than-expected organic growth of 4.2%, exceeding the forecast of 3.5%.
Strategic Review and Future Outlook: The company is exploring strategic options for its Terpene business to enhance margins and has reaffirmed its growth targets for 2025 and 2028, aiming for organic growth of 5% to 7% and maintaining an EBITDA margin around 21%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
